图标通过成本效益和创新的解决方案提供了快速的市场准入

The importance of biologics in today’s drug development market is evident from the statistics. As the number of biologics going off patent increases, biosimilar medicines promise to be an attractive offering to healthcare organisations, physicians and patients by providing greater choice and a more cost effective alternative.

图标生物仿制物经验

  • 350.

    生物学研究涉及9,500个地点
  • 28,000

    患者参与其中
  • 38+

    Biosimilar studies including early phase and phase III

不断发展的监管环境

FDA关于生物仿制物的指导指导(2017年1月)在监管要求提供更明显的清晰度,数据提案国的类型需要提供展示互换性。

Integrated services

ICON provides clients with a fully integrated approach to the development of biosimilars. We can help you to choose the right target molecule and the optimal development and commercial strategy. Our experts have the insight needed in drug development, regulatory conditions and commercialisation along with the operational capability to deliver your programmes on time and within budget.

  • 药物开发咨询: We have a strong track record in strategically advising clients through the development continuum.
  • 早期服务与临床药理学: ICON specialises in the strategy and delivery of early-phase clinical development services to enable informed, timely decision making for our clients.
  • III期临床研究服务: We provide clients with a flexible, best-in-class approach to improve cycle times, constrain costs and reduce risks.
  • Bioanalytical Laboratories: ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.
  • 监管事务:我们致力于提供卓越的质量监管服务,使我们的客户能够加快药物开发计划。
  • 真实世界智力:图标提供运营和咨询服务,以实现产品授权,通过战略设计和交付现实世界的证据研究和后期研究。
  • Value Access and Outcomes:集成市场准入,定价,通信和健康经济专家提供战略指导和战术解决方案,以展示您的产品价值,并支持全球的品牌成功。